Entera Bio grants COO options for 200,000 shares
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. granted Chief Operating Officer Hillel Galitzer stock options to buy 200,000 ordinary shares at $1.3700 per share, expiring 2036-05-07. The Board approved the grant on May 7, 2026, contingent on a Form S-8 registration that became effective August 7, 2026. The options vest over three years starting May 7, 2026, with one third vesting on May 7, 2027 and the remaining two-thirds vesting quarterly, subject to full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 200,000 shares
Grant/Award
1 txn
Insider
Galitzer Hillel
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 200,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 200,000 contracts (Direct)
Footnotes (1)
- F1. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).
Key Figures
Stock options granted: 200,000 options
Exercise price: $1.3700 per share
Underlying ordinary shares: 200,000 shares
+3 more
6 metrics
Stock options granted
200,000 options
Grant of stock options to the Chief Operating Officer
Exercise price
$1.3700 per share
Conversion or exercise price of the granted stock options
Underlying ordinary shares
200,000 shares
Ordinary shares underlying the option grant
Options expiration date
2036-05-07
Date on which the granted options expire
Vesting period start
May 7, 2026
Three-year vesting period for the options begins on this date
First vesting date
May 7, 2027
One third of the options vest on this date
Key Terms
Stock Option (right to buy), Registration Statement on Form S-8, Change in Control, 2018 Equity Incentive Plan
4 terms
Stock Option (right to buy) financial
"Reported security_title "Stock Option (right to buy)" for the COO grant"
Registration Statement on Form S-8 regulatory
"Subject to the filing of a Registration Statement on Form S-8 registering the shares"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
Change in Control financial
"Options are subject to full acceleration upon a Change in Control under the plan"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2018 Equity Incentive Plan financial
"Change in Control as defined in the Company's 2018 Equity Incentive Plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Entera Bio (ENTX) grant to COO Hillel Galitzer?
Entera Bio granted COO Hillel Galitzer stock options to purchase 200,000 ordinary shares at an exercise price of $1.3700 per share. These options provide equity-based compensation and expire on 2036-05-07, aligning him with long-term shareholder value.
What is the exercise price of the ENTX stock options granted to the COO?
The exercise price of the options granted to the COO is $1.3700 per share. Each option allows the purchase of one ordinary share at this price, as set in the grant approved by Entera Bio’s Board of Directors on May 7, 2026.
How do the ENTX options granted to the COO vest over time?
The options vest over a three-year period beginning May 7, 2026. One third vests on May 7, 2027, and the remaining two-thirds vest ratably on a quarterly basis over the following two years, subject to continued service and plan terms.
Do the ENTX COO option grants accelerate on a Change in Control?
Yes. The options are subject to full acceleration upon a Change in Control, as defined in Entera Bio’s 2018 Equity Incentive Plan. If such a transaction occurs, all unvested options would become fully vested under the plan’s change-in-control provisions.
Were the ENTX COO option grants contingent on any securities registration?
Yes. The grant was approved on May 7, 2026 but was subject to filing a Registration Statement on Form S-8 covering the underlying shares. That registration occurred on August 7, 2026, after which the option grant became effective.
AI-generated analysis. How Rhea-AI works. Not financial advice.
